GenSensor a DeepTech start-up and Servier, a global pharmaceutical group, today announced a new initiative in the form of expert mentoring to accelerate the industrialization of an innovative Process Analytical System to better produce biomedicine.
Following the 7th France Bioproduction Congress organized by PolePharma (top industrial cooperation for drugs in Europe) and MediCen (health competitiveness cluster, Île-de-France, France), Servier has decided to follow GenSensor in their development, sharing bioproduction pitfalls and constraints.
Building an exchange/a sharing place between a start-up and a pharmaceutical group – that produces its drugs – is a way to accelerate the development of the product while ensuring its compatibility and deployment in an industrial setting. It is an opportunity for GenSensor to co-construct an innovative tool fully aligned with the needs of innovative drug producers.
GenSensor is a DeepTech start-up that develops innovative in-line Process Analytical Technology (PAT). Its technology is based on real time cell sequencing during production. GenSensor aims to improve the production of biological drugs. GenSensor is supported by Atlanpole and financed by the BPI. GenSensor is part of France’s 2030 national health strategy to accelerate biotherapies and bioproduction of innovative therapies by improving production yields and capacity, reducing production costs.